Abstract
BackgroundIguratimod (IGU) is widely used in the treatment of rheumatoid arthritis (RA) and has been considered the first-line treatment option in many countries. The efficacy and safety of IGU combination...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
